JP5148686B2 - β−アミノ基を含むＤＰＰ−ＩＶ阻害剤、その製造方法及びそれを有効成分として含む糖尿または肥満予防及び治療用医薬組成物 - Google Patents

β−アミノ基を含むＤＰＰ−ＩＶ阻害剤、その製造方法及びそれを有効成分として含む糖尿または肥満予防及び治療用医薬組成物 Download PDF

Info

Publication number
JP5148686B2
JP5148686B2 JP2010503979A JP2010503979A JP5148686B2 JP 5148686 B2 JP5148686 B2 JP 5148686B2 JP 2010503979 A JP2010503979 A JP 2010503979A JP 2010503979 A JP2010503979 A JP 2010503979A JP 5148686 B2 JP5148686 B2 JP 5148686B2
Authority
JP
Japan
Prior art keywords
amino
trifluorophenyl
butanoyl
piperazin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010503979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500508A (ja
JP2011500508A5 (enExample
Inventor
ジェ キム，ヒュン
ヨン カク，ウ
イェル シン，チャン
キム，ハドン
ピル ミン，ジョン
ジン パク，キュン
ヨン イ，ジェ
チョイ，ソン−ヒェン
ヒュン ユン，テ
キム，ヘ−スン
ミュン ジャン，ジ
キム，ミ−キュン
ソン，ムン−ホ
キム，スン−ヘ
ユ，ムヒ
Original Assignee
ドン・ア・ファーム・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドン・ア・ファーム・カンパニー・リミテッド filed Critical ドン・ア・ファーム・カンパニー・リミテッド
Publication of JP2011500508A publication Critical patent/JP2011500508A/ja
Publication of JP2011500508A5 publication Critical patent/JP2011500508A5/ja
Application granted granted Critical
Publication of JP5148686B2 publication Critical patent/JP5148686B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010503979A 2007-04-19 2008-04-18 β−アミノ基を含むＤＰＰ−ＩＶ阻害剤、その製造方法及びそれを有効成分として含む糖尿または肥満予防及び治療用医薬組成物 Active JP5148686B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20070038462 2007-04-19
KR10-2007-0038462 2007-04-19
PCT/KR2008/002203 WO2008130151A1 (en) 2007-04-19 2008-04-18 Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity

Publications (3)

Publication Number Publication Date
JP2011500508A JP2011500508A (ja) 2011-01-06
JP2011500508A5 JP2011500508A5 (enExample) 2011-07-21
JP5148686B2 true JP5148686B2 (ja) 2013-02-20

Family

ID=39875638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503979A Active JP5148686B2 (ja) 2007-04-19 2008-04-18 β−アミノ基を含むＤＰＰ−ＩＶ阻害剤、その製造方法及びそれを有効成分として含む糖尿または肥満予防及び治療用医薬組成物

Country Status (15)

Country Link
US (1) US8030315B2 (enExample)
EP (1) EP2142519B1 (enExample)
JP (1) JP5148686B2 (enExample)
KR (1) KR101007497B1 (enExample)
CN (2) CN101663282B (enExample)
AU (1) AU2008241692B2 (enExample)
BR (1) BRPI0810246B1 (enExample)
CA (1) CA2683696C (enExample)
ES (1) ES2526338T3 (enExample)
IL (1) IL201524A (enExample)
MX (1) MX2009011276A (enExample)
NZ (1) NZ580701A (enExample)
PT (1) PT2142519E (enExample)
RU (1) RU2419615C1 (enExample)
WO (1) WO2008130151A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101054911B1 (ko) * 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
CN102378751B (zh) * 2009-03-30 2014-08-20 东亚St株式会社 用于制备二肽基肽酶-iv抑制剂和中间体的改进方法
SG174973A1 (en) * 2009-03-30 2011-11-28 Dong A Pharm Co Ltd Improved method for manufacturing dipeptidyl peptidase-iv inhibitor and intermediate
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20110107287A (ko) * 2010-03-24 2011-09-30 동아제약주식회사 비알콜성 지방간 질환의 예방 및 치료용 약학적 조성물
KR101180174B1 (ko) 2010-04-23 2012-09-05 동아제약주식회사 신규한 벤즈아미드 유도체
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101290029B1 (ko) 2011-01-20 2013-07-30 에스티팜 주식회사 시타글립틴의 중간체 제조방법
CN102321014A (zh) * 2011-05-27 2012-01-18 沈阳亿灵医药科技有限公司 新型双苯基吡啶类衍生物
WO2012166420A1 (en) * 2011-05-27 2012-12-06 Merck Sharp & Dohme Corp. Phosphoric acid salts of sitagliptin
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
BR112015032410B8 (pt) * 2013-06-26 2021-10-26 Dong A St Co Ltd Uso de uma composição farmacêutica compreendendo inibidores de dpp-iv no preparo de um medicamento para prevenção ou tratamento de doenças renais
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
KR101709127B1 (ko) 2015-06-16 2017-02-22 경동제약 주식회사 Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
CN107382757A (zh) * 2017-08-11 2017-11-24 苏州信恩医药科技有限公司 不对称烯丙基取代反应在依格列汀中间体合成中的应用
CN107417554A (zh) * 2017-08-15 2017-12-01 苏州信恩医药科技有限公司 一种依格列汀中间体的合成方法
KR20220165346A (ko) 2021-06-08 2022-12-15 동아에스티 주식회사 에보글립틴의 안정성이 개선된 제제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090082A1 (en) * 2000-05-25 2001-11-29 F. Hoffmann-La Roche Ag Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
DE60114413T2 (de) * 2000-05-25 2006-07-27 F. Hoffmann-La Roche Ag Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
JP2002088070A (ja) * 2000-09-18 2002-03-27 Mitsubishi Rayon Co Ltd 新規ピペラジノン誘導体およびその製造方法
ATE370141T1 (de) * 2002-10-07 2007-09-15 Merck & Co Inc Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase
PL216527B1 (pl) 2002-10-18 2014-04-30 Merck & Co Inc Związki ß-aminoheterocykliczne i kompozycja farmaceutyczna
CA2533893A1 (en) 2003-07-31 2005-02-10 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1541143A1 (en) * 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Dpp-iv inhibitors
EP1695969A4 (en) * 2003-12-11 2008-11-26 Mitsubishi Tanabe Pharma Corp ALPHA-AMINO-ACID DERIVATIVES AND THEIR USE AS MEDICINE
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
EP1604989A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
GB0413389D0 (en) * 2004-06-16 2004-07-21 Astrazeneca Ab Chemical compounds
US20090124601A1 (en) 2005-03-29 2009-05-14 Song Zhiguo J Tartaric Acid Salts of a Dipeptidyl Peptidase-IV Inhibitor
JP2008031064A (ja) * 2006-07-27 2008-02-14 Astellas Pharma Inc ジアシルピペラジン誘導体

Also Published As

Publication number Publication date
NZ580701A (en) 2011-07-29
PT2142519E (pt) 2014-12-11
CN102516184A (zh) 2012-06-27
BRPI0810246B1 (pt) 2021-11-30
US8030315B2 (en) 2011-10-04
AU2008241692A1 (en) 2008-10-30
WO2008130151A1 (en) 2008-10-30
BRPI0810246A2 (pt) 2015-08-18
AU2008241692B2 (en) 2011-02-10
HK1138272A1 (en) 2010-08-20
CA2683696C (en) 2012-05-22
HK1172613A1 (en) 2013-04-26
CN101663282A (zh) 2010-03-03
RU2419615C1 (ru) 2011-05-27
EP2142519A4 (en) 2011-07-13
JP2011500508A (ja) 2011-01-06
CN101663282B (zh) 2012-02-15
EP2142519A1 (en) 2010-01-13
US20100120790A1 (en) 2010-05-13
CA2683696A1 (en) 2008-10-30
IL201524A (en) 2014-09-30
MX2009011276A (es) 2010-01-15
EP2142519B1 (en) 2014-09-24
ES2526338T3 (es) 2015-01-09
IL201524A0 (en) 2010-05-31
KR20080094604A (ko) 2008-10-23
CN102516184B (zh) 2015-03-25
KR101007497B1 (ko) 2011-01-12

Similar Documents

Publication Publication Date Title
JP5148686B2 (ja) β−アミノ基を含むＤＰＰ−ＩＶ阻害剤、その製造方法及びそれを有効成分として含む糖尿または肥満予防及び治療用医薬組成物
US10398677B2 (en) N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP1680418B1 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
US12291518B2 (en) Thyroid hormone receptor agonists and use thereof
CA2867114C (en) Piperidine derivatives for gpr119 agonist
JP2002363157A (ja) 新規α−アミノ酸化合物、その調製方法及びそれを含有する医薬組成物
JP2008031064A (ja) ジアシルピペラジン誘導体
TW200938530A (en) Pyrrolidine compounds
US10654834B2 (en) Non-systemic TGR5 agonists
JP2008063256A (ja) β‐アミノ酸誘導体
JP5128126B2 (ja) 置換ジケトピペラジンオキシトシンアンタゴニストとしてのその使用
US11634428B2 (en) Deuterated angiotensin-converting enzyme-2 (ACE-2) inhibitors
HK1138272B (en) Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity
HK1172613B (en) Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity
US20260001859A1 (en) Small molecule inhibitors of mammalian slc6a19 function
WO2025196447A1 (en) Thiadiazoles as glutaminase 1 inhibitors
EP3966205A1 (en) Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
CN105753842A (zh) 三氮唑甲基尿嘧啶衍生物、其制备方法及在医药上的应用
TW201706279A (zh) 經取代的氨基磷酸酯類衍生物、其製備方法及其應用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121022

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121128

R150 Certificate of patent or registration of utility model

Ref document number: 5148686

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151207

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250